FDC surged 4.27% to Rs 30.55 at 13:50 IST on BSE after the company said it has received approval from the US Food & Drug Administration for its abbreviated new drug application for Timolol Maleate ophthalmic solution.
The stock hit a high of Rs 31.45 and a low of Rs 28.70 so far during the day. The stock had a 52-week high of Rs 53.60 on
The company’s current equity is Rs 19.14 crore. Face value per share is Rs 1.
The current price of Rs 30.55 discounts its Q3 December 2007 annualised EPS of Rs 4.42, by a PE multiple of 4.66.
Timolol Maleate is a nonselective beta-blocking drug, used as a primary line of treatment of glaucoma.
FDC’s net profit rose 59.7% to Rs 21.15 crore on 20.4% increase in net sales to Rs 121.50 crore in Q3 December 2007 over Q3 December 2006.
The company manufactures electral, oral rehydration salt (ORS). It also manufactures bulk drugs, formulations and food products.
No comments:
Post a Comment